PPARGC1B

PPARGC1B (PGC-1β/PERC) is a transcriptional coactivator that drives mitochondrial biogenesis and energy-metabolic programs in hepatocytes and adipocytes (PMID:27885055, PMID:38190589). It selectively coactivates estrogen receptor alpha (ERα), but not ERβ, through two LXXLL motifs that engage the ERα AF2 domain in an estrogen-dependent manner, and it likewise enhances ERRγ activity via the receptor's constitutive AF-2 domain (PMID:11854298, PMID:12470660). Through this ERα-coactivating function, PPARGC1B mediates the stimulatory effect of 17β-estradiol on hepatic mitochondrial content and oxidative capacity, an effect specific to PPARGC1B rather than PGC1A (PMID:27885055). A coding variant (R265Q) increases ERα coactivation and estradiol-dependent association with ERα, linking sequence variation to coactivator output (PMID:27027322). In adipogenic and brown-adipocyte contexts, PPARGC1B is required for differentiation and is post-transcriptionally repressed by ZFP36L1 binding to AU-rich elements in its 3'-UTR (PMID:29993187); CRISPR allelic editing of a cis-eQTL variant (rs10071329 G/G) that raises PPARGC1B expression increases triglyceride accumulation, mitochondria-encoded gene expression, basal and norepinephrine-stimulated respiration, and norepinephrine-stimulated lipolysis, establishing a dose-dependent role in brown adipocyte mitochondrial function and lipolysis (PMID:38190589).

1. 2002 High

   Established that PPARGC1B is a nuclear-receptor coactivator with selectivity, answering which receptors it engages and through what interface.

   Evidence Transfection coactivation assays with LXXLL motif and ERα AF2 domain mutagenesis; receptor truncation and in vitro binding for ERRγ

   PMID:11854298 PMID:12470660

   Open questions at the time

   • Endogenous target genes of ERα/ERRγ coactivation not defined
   • Selectivity for ERα over ERβ mechanistically explained only at the LXXLL/AF2 level
2. 2016 Medium

   Connected PPARGC1B coactivator activity to a physiological output by showing it is specifically required for estrogen-induced hepatic mitochondrial biogenesis.

   Evidence siRNA knockdown of PPARGC1B versus PGC1A in HepG2 cells with mitochondrial assays, plus ovariectomized rat E2 model

   PMID:27885055

   Open questions at the time

   • Direct target genes downstream of E2/PPARGC1B not mapped
   • Single-lab evidence
3. 2016 Medium

   Demonstrated that a coding variant modulates coactivator strength, linking PPARGC1B sequence variation to ERα interaction and transcriptional output.

   Evidence Luciferase ERE-reporter assays in 293T and co-precipitation with HA-tagged variant constructs

   PMID:27027322

   Open questions at the time

   • Physiological/in vivo consequence of R265Q not established
   • Mechanism by which R265Q enhances ERα binding unresolved
4. 2018 Medium

   Identified post-transcriptional control of PPARGC1B and a requirement for it in adipogenesis, defining an upstream regulatory layer.

   Evidence ZFP36L1 knockdown/overexpression, 3'-UTR AU-rich element analysis, and PPARGC1B knockdown in MSC adipogenesis assays

   PMID:29993187

   Open questions at the time

   • Direct ZFP36L1–3'UTR binding shown indirectly
   • Coactivation targets driving adipogenesis not specified
5. 2024 High

   Established a causal, dose-dependent role for PPARGC1B in brown adipocyte mitochondrial function and lipolysis using allelic editing of a cis-regulatory variant.

   Evidence Scarless CRISPR/Cas9 editing of rs10071329 in a human brown adipocyte line with expression, respiration, and lipolysis readouts

   PMID:38190589

   Open questions at the time

   • Transcription factor mediating the cis-eQTL effect not identified
   • In vivo metabolic consequence in humans not tested

• The genome-wide direct target genes of PPARGC1B coactivation and how its activity is integrated across hepatic versus adipose tissues remain undefined.
• No ChIP/genomic target map in the corpus
• Tissue-specific receptor partners beyond ERα/ERRγ uncharacterized